Mathieu Varache, Siân Rizzo, Edward J Sayers, Lucy Newbury, Anna Mason, Chia-Te Liao, Emilie Chiron, Nathan Bourdiec, Adam Jones, Donald J Fraser, Philip R Taylor, Arwyn T Jones, David W Thomas, Elaine L Ferguson
The acute kidney injury (AKI) and dose-limiting nephrotoxicity, which occurs in 20-60% of patients following systemic administration of colistin, represents a challenge in the effective treatment of multi-drug resistant Gram-negative infections. To reduce clinical toxicity of colistin and improve targeting to infected/inflamed tissues, we previously developed dextrin-colistin conjugates, whereby colistin is designed to be released by amylase-triggered degradation of dextrin in infected and inflamed tissues, after passive targeting by the enhanced permeability and retention effect...
April 18, 2024: RSC Pharm